These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27450506)

  • 1. Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis.
    Yu S; Luo H; Pan M; Luis AP; Xiong Z; Shuai P; Zhang Z
    Int J Clin Pharm; 2016 Oct; 38(5):1035-43. PubMed ID: 27450506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
    Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
    JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy.
    Chen WC; Cheng JS; Chiang PH; Tsay FW; Chan HH; Chang HW; Yu HC; Tsai WL; Lai KH; Hsu PI
    PLoS One; 2015; 10(6):e0131545. PubMed ID: 26121480
    [TBL] [Abstract][Full Text] [Related]  

  • 4.  Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation.
    Yang C; Qin B; Yuan Z; Chen L; Zhou HY
    Ann Hepatol; 2016; 15(4):501-11. PubMed ID: 27236149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
    Zhang MY; Zhu GQ; Shi KQ; Zheng JN; Cheng Z; Zou ZL; Huang HH; Chen FY; Zheng MH
    Oncotarget; 2016 May; 7(21):30642-58. PubMed ID: 27121321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy.
    Li HR; Huang JJ; Guo HQ; Zhang X; Xie Y; Zhu HL; Zhai LZ; Pu XX; Huang Y; Guo CC; Lin TY
    J Viral Hepat; 2011 Dec; 18(12):877-83. PubMed ID: 21054683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
    Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
    J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of entecavir in hepatitis B virus reactivation of a patient with non-Hodgkin's lymphoma.
    Gozdas HT; Arpaci E
    World J Gastroenterol; 2015 Sep; 21(35):10251-2. PubMed ID: 26401092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
    Zhang MY; Zhu GQ; Zheng JN; Cheng Z; Van Poucke S; Shi KQ; Huang HH; Chen FY; Zheng MH
    Expert Rev Anti Infect Ther; 2017 May; 15(5):503-513. PubMed ID: 28317397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: a systematic review and meta-analysis.
    Li H; Zhang HM; Chen LF; Chen YQ; Chen L; Ren H; Hu HD
    Clin Res Hepatol Gastroenterol; 2015 Feb; 39(1):80-92. PubMed ID: 25199680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of the prophylactic effect of nucleosides against reactivation of HBV in HBsAg-positive patients with non-hepatic tumors after chemotherapy].
    Zhang HY; Liu ZG; Zhang Z; Gong HY
    Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):459-62. PubMed ID: 20819491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
    Chen FW; Coyle L; Jones BE; Pattullo V
    Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
    Long M; Jia W; Li S; Jin L; Wu J; Rao N; Feng H; Chen K; Deng H; Liu F; Su F; Song E
    Breast Cancer Res Treat; 2011 Jun; 127(3):705-12. PubMed ID: 21445574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
    Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
    Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
    An J; Shim JH; Kim SO; Choi J; Kim SW; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Med Virol; 2016 Sep; 88(9):1576-86. PubMed ID: 26945543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy.
    Cai Q; Chen K; Chen J; Wu S; Geng Q; Huang H; Lin T; Jiang W; Xia Z; Duan H; Rao H; Yao M; Hu L
    PLoS One; 2016; 11(10):e0164210. PubMed ID: 27711135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
    Yeo W; Ho WM; Hui P; Chan PK; Lam KC; Lee JJ; Johnson PJ
    Breast Cancer Res Treat; 2004 Dec; 88(3):209-15. PubMed ID: 15609123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
    Huang ZB; Zhao SS; Huang Y; Dai XH; Zhou RR; Yi PP; Chen RC; Li WT; Zhang BX; Li N; Fan XG
    Clin Ther; 2013 Dec; 35(12):1997-2006. PubMed ID: 24238791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis.
    Coiffier B
    Cancer Invest; 2006; 24(5):548-52. PubMed ID: 16939967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine.
    Geipel A; Seiz PL; Niekamp H; Neumann-Fraune M; Zhang K; Kaiser R; Protzer U; Gerlich WH; Glebe D;
    Antivir Ther; 2015; 20(8):779-87. PubMed ID: 25560463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.